Compare Expeditors International of Wshngtn Inc (EXPD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs GSK plc — how do they compare? Expeditors International of Wshngtn Inc trades at $192.67 (market cap $25.18B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.6× Expeditors International of Wshngtn Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and GSK plc for 93 Days on average.
| EXPD | GSK | |
|---|---|---|
Market Cap | $25.18B | $91.88B |
Volume | 1,003,557 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $194.12 | $61.18 |
52-Week Low | $113.13 | $43.24 |
Typical Hold Time | 43 Days | 93 Days |
Enterprise Value | $24.72B | $111.88B |
Dividend Yield | 0.84% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $193.52, up 1.4% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.20. Revenue grew to $11.07B in 2025, while net income held steady at $810M. The company maintains strong profitability with a 42.6% ROE, though valuation multiples like the 28.2 P/E are elevated relative to historical norms.
Outlook is mixed; efficiency initiatives and airfreight demand support growth, but analyst consensus is cautious with a $179.43 price target below the current price. Key risks include reliance on global trade cycles and potential margin pressure. Upside depends on continued earnings beats and sustained freight market strength.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
